ZURA - NASDAQ

Zura Bio Limited

ZURA·NASDAQ

$3.86

-5.9%

HealthcareBiotechnology

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$250.98M

EPS-1.0600

P/E Ratio-3.64

Earnings Date08/13/2026

zura

Net Common Stock Issuance

Last Annual Value

5.20M

3-Year CAGR

5-Year CAGR

-48%

10-Year CAGR

-28%

Adjust for Inflation

Zura Bio Limited Competitors Analysis of Net Common Stock Issuance

ZURA · NASDAQ

Company	Net Common Stock Issuance	CAGR 3Y	CAGR 5Y	CAGR 10Y
Zura Bio Limited NASDAQ:ZURA	5.20M	-64.5%	-48.3%	N/A
Pyxis Oncology, Inc. NASDAQ:PYXS	742.00K	-50.5%	-65.5%	N/A
Caribou Biosciences, Inc. NASDAQ:CRBU	4.82M	-68.4%	-56.8%	N/A
Neonc Technologies Holdings, Inc. NASDAQ:NTHI	17.16M	3265.8%	N/A	N/A
SELLAS Life Sciences Group, Inc. NASDAQ:SLS	86.82M	57.5%	57.3%	N/A
Entrada Therapeutics, Inc. NASDAQ:TRDA	887.00K	-64.2%	-65.8%	N/A
Aardvark Therapeutics, Inc. Common Stock NASDAQ:AARD	89.25M	N/A	N/A	N/A
Immuneering Corporation NASDAQ:IMRX	226.58M	100.3%	13.5%	N/A
Tenaya Therapeutics, Inc. NASDAQ:TNYA	108.41M	203.8%	-10.5%	N/A
Sagimet Biosciences Inc. NASDAQ:SGMT	275.00K	-85.5%	N/A	N/A
Assembly Biosciences, Inc. NASDAQ:ASMB	174.67M	133.7%	27.0%	102.2%

Zura Bio Limited Fair Value Envelope

ZURA · NASDAQ

Our analysis suggests that ZURA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.86, this represents a potential HIDDEN relative to our calculated worth for Zura Bio Limited.

HIDDEN

Intrinsic Value

Current Price: $3.86

Related Guides

Blog Categories

Continue your ZURA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.